Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1200 Monotherapy in Advanced Solid Tumors (China) Phase I/II
CTR20241154Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lucansatuzumab in gastric cancer (GC), esophagogastric junction cancer, esophageal cancer, biliary cancer, pancreatic adenocarcinoma (PDAC), sponsored by Merck & Co.. Started Apr 2024; status: terminated.
02
Drugs
lucansatuzumab
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal cancerbiliary cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20241154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241154.